Form 4: Soligenix CSO Acquires 20,000 Stock Options

Soligenix's Chief Scientific Officer, Oreola Donini, acquired 20,000 stock options on December 12, 2024, at an exercise price of $3.31.

Summary

• Oreola Donini, the Chief Scientific Officer of Soligenix, Inc., acquired 20,000 stock options on December 12, 2024.
• The exercise price for these options is $3.31 per share.
• The options vest over time, with 25% vesting immediately and the remaining 75% vesting in 12 equal installments every three months starting from December 12, 2024.
• The options expire on December 11, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The acquisition of stock options by a key executive like the CSO can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in the biotechnology industry, similar to practices at companies like Amgen, Gilead, and Regeneron.
• The vesting schedule of 25% immediately and the remainder over three years is also a typical vesting structure.

Stakeholder Impact

• The stock option grant could positively impact shareholder sentiment by demonstrating management's commitment to the company's success.

Key Dates

Keywords

stock options, insider trading, executive compensation, Soligenix, SNGX, Oreola Donini